Isconova to Present at "Influenza Vaccines for the World Conference"
Published: Oct 11, 2012
Karin Lövgren-Bengtsson, Chief Scientific Officer of Isconova will present ‘Clinical and preclinical experience with Isconova’s proprietary adjuvant Matrix-M™’ focusing on the results of clinical studies on Pandemic influenza and seasonal influenza vaccine in elderly with Isconova’s proprietary adjuvant Matrix-M™.
The presentation will take place at day 3, session 11, from 14:00 to 14:20 in Palacio de Congresos De Valencia, Valencia, Spain.
Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops novel vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s Matrix technology was launched in the veterinary market in 2006. In the human vaccine market, a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix-M™. The Company is headquartered in Uppsala, Sweden. For more information, visit www.isconova.com
Sven Andréasson, CEO, +46 701 60 60 60,